Hormonal
Regular physical exercise training significantly improves insulin sensitivity and reduces cardiovascular risk factors (including blood pressure, HbA1c, and lipid profiles) in subjects with insulin resistance, metabolic syndrome, or type 2 diabetes.
Engage in regular physical activity, prioritizing aerobic exercise for metabolic syndrome components. Aim for higher volumes (approaching 170 minutes/week) if possible, as duration appears to drive insulin sensitivity improvements more than intensity alone. Combine exercise with dietary changes for best weight maintenance results. Do not abandon exercise if scale weight changes are modest; the cardiovascular and metabolic benefits (lower BP, better insulin sensitivity) are significant even without major weight loss.
physical training has been shown to ameliorate insulin effects in insulin-resistant subjects... physical training has been shown to ameliorate insulin effects in insulin-resistant subjects. Interestingly, it has been documented that intensity and volume of exercise program have different effects on insulin sensitivity... all training programs enhanced the insulin sensitivity index.
Why this rating
The paper cites multiple meta-analyses and large randomized controlled trials (e.g., Da Qing, Finnish Diabetes Prevention, Look AHEAD).
Source
Modulation of Insulin Sensitivity by Exercise Training: Implications for Cardiovascular Prevention
Guido Iaccarino et al. · Journal of Cardiovascular Translational Research · 2020
DOI 10.1007/s12265-020-10057-w
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →